Comments
Glenmark Pharmaceuticals Ltd today said that its subsidiary has received approval from the US health regulator to sell generic versions of AstraZeneca’s Zomig and Zomig ZMT tablets, a migraine drug, in the American market.
Glenmark Generics Inc., a subsidiary of Glenmark, has received approval from the US Food and Drug Administration (USFDA) for Zolmitriptan tablets and Zolmitriptan orally disintegrating tablets, the company said in a statement today.
“Glenmark will commence distribution of the product immediately,” the Mumbai-based firm said.
Zolmitriptan tablets and Zolmitriptan ODT are indicated for the acute treatment of migraine headaches in adults.
According to IMS Health, for the 12-month period ended December 2012, the products garnered annual sales of $176 million. Glenmark’s current portfolio consists of 85 products authorised for distribution in the US market.
Shares of Glenmark ended the session at Rs 558.25 on the BSE, up 1.94 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.